<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ORBAX- orbifloxacin tablet, coated </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<h1>ORBAX<span class="Sup">® </span>Tablets <br>(orbifloxacin) <br>For Oral Use in Dogs and Cats Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">NADA #141-081, Approved by FDA.</span></p>
<p><span class="Bold">Federal law prohibits the extra label use of this drug in food-producing animals.</span></p>
<p><span class="Bold">CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION:</span> Orbifloxacin is a synthetic broad-spectrum antibacterial agent from the class of fluoroquinolone carboxylic acid derivatives. Orbifloxacin is the international nonproprietary name for 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(<span class="Italics">cis</span>-3,5-dimethyl- 1-piperazinyl)-4-oxoquinoline-3-carboxylic acid. The chemical formula for orbifloxacin is C<span class="Sub">19</span>H<span class="Sub">20</span>F<span class="Sub">3</span>N<span class="Sub">3</span>O<span class="Sub">3 </span>and its molecular weight is 395.38. The compound is slightly soluble in water; however, solubility increases in both acidic and alkaline conditions. The compound has two dissociation constants (pKa's): 5.95 and 9.01.</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26e81d72-bb96-497d-ac2f-c9d138f97c09&amp;name=orbax-01.jpg"></p>
<p><span class="Bold">Figure 1. Chemical structure of orbifloxacin.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS:</span> ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets are indicated for the management of diseases in dogs and cats associated with bacteria susceptible to orbifloxacin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">EFFICACY CONFIRMATION:</span> Clinical efficacy was established in skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span> (<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>) in the dog and cat, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (<span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>) in the dog, associated with bacteria susceptible to orbifloxacin. Specific bacterial pathogens isolated in clinical field trials are listed in the <span class="Bold">MICROBIOLOGY</span> section.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION:</span> For routine out-patient treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by a susceptible organism, in an otherwise healthy dog or cat, the dose of ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets is 2.5 to 7.5 mg/kg of body weight administered once daily. (See <span class="Bold"><a href="#DI">DRUG INTERACTIONS</a></span> and <span class="Bold"><a href="#TAS">TARGET ANIMAL SAFETY</a></span>). In the cat, ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets and ORBAX<span class="Sup">® </span>(orbifloxacin) Oral Suspension are not bioequivalent. On a mg/kg basis, ORBAX<span class="Sup">® </span>(orbifloxacin) Oral Suspension provides lower and more variable plasma levels of orbifloxacin than ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets. The determination of dosage for any particular patient must take into consideration such factors as the severity and nature of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, the susceptibility of the causative organism, and the integrity of the patient's host-defense mechanisms. Antibiotic susceptibility of the pathogenic organism(s) should be determined prior to use of this preparation. Therapy with ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets may be initiated before results of these tests are known. Once results become available, continue with appropriate therapy.</p>
<p>For the treatment of skin and associated <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span>, ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets should be given for two (2) to three (3) days beyond the cessation of clinical signs to a maximum of 30 days. For the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets should be administered for at least 10 consecutive days. If no improvement is seen within five (5) days, the diagnosis should be re-evaluated and a different course of therapy considered.</p>
<p>To administer a total daily dose of 2.5 mg/kg, ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets may be dispensed as indicated in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Dose Table for ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets (2.5 mg/kg total daily dose)</span></caption>
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="9%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="9%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="9%">
<thead>
<tr class="First"><th align="left" colspan="10">WEIGHT OF DOG/CAT (lbs)</th></tr>
<tr class="Last">
<th align="left"></th>
<th align="center">5</th>
<th align="center">10</th>
<th align="center">20</th>
<th align="center">30</th>
<th align="center">40</th>
<th align="center">50</th>
<th align="center">60</th>
<th align="center">90</th>
<th align="center">120</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td align="left">No. of 22.7 mg tablets</td>
<td align="center"></td>
<td align="center">½</td>
<td align="center">1</td>
<td align="center">1½</td>
<td align="center">2</td>
<td align="center">2½</td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">No. of 68 mg tablets</td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">½</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">1½</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-6"></a><p></p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY: Pharmacokinetics in healthy adult beagle dogs and healthy adult cats:</span> In fasted animals, orbifloxacin is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. Absorption of orally administered orbifloxacin increases proportionately with dose (exhibits linear pharmacokinetics) up to 37.5 mg/kg when given daily for 30 days. The absolute bioavailability (F) of an oral dose is approximately 100%. Peak plasma concentrations are usually attained within 1 hour of administration. The effects of concomitant feeding on the absorption of orbifloxacin have not been studied. Divalent cations are generally known to diminish the absorption of fluoroquinolones. (See <span class="Bold"><a href="#DI">DRUG INTERACTIONS</a>.</span>) The relatively large volume of distribution at steady state (V<span class="Sub">ss</span>) is indicative of a widespread distribution and penetration into body tissues. Within 24 hours of administration, approximately 40% of an oral dose was excreted into the urine unchanged in dogs with normal renal function. This supports the efficacy of orbifloxacin in the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Based on the plasma elimination half-life and the dosing interval, negligible drug accumulation is expected with multiple dosing. Pharmacokinetic parameters estimated in a randomized two-period, two-sequence crossover study using single intravenous and oral doses are summarized in Tables 2 and 3 and Figures 2 and 3.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Mean Pharmacokinetic Parameters Estimated in 12 Adult Beagle Dogs and 12 Adult Cats After a Single IV Bolus of Orbifloxacin at 2.5 mg/kg</span></caption>
<col align="left" valign="bottom" width="34%">
<col align="left" valign="bottom" width="33%">
<col align="left" valign="bottom" width="33%">
<thead><tr class="First Last">
<th align="left">Pharmacokinetic Parameter</th>
<th align="left">Dog Estimate (SD)</th>
<th align="left">Cat Estimate (SD)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Total body clearance, mL/min/kg</td>
<td align="left">2.9 ± 0.2</td>
<td align="left">4.09 ± 0.7</td>
</tr>
<tr>
<td align="left">Volume of distribution at steady state, V<span class="Sub">ss </span>(L/kg)</td>
<td align="left">1.2 ± 0.2</td>
<td align="left">1.3 ± 0.13</td>
</tr>
<tr>
<td align="left">AUC <span class="Sub">0</span> - <span class="Sub">∞</span>(µg∙h/mL)</td>
<td align="left">14.3 ± 0.9</td>
<td align="left">10.6 ± 2.4</td>
</tr>
<tr class="Last">
<td align="left">Terminal plasma elimination half-life, t<span class="Sub">½</span> (hrs)</td>
<td align="left">5.4 ± 1.1</td>
<td align="left">4.5 ± 1.8</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="75%">
<caption><span>Table 3: Mean Pharmacokinetic Parameters Estimated in 12 Adult Beagle Dogs and 12 Adult Cats After a Single Oral Dose of Orbifloxacin at 2.5 mg/kg</span></caption>
<col align="left" valign="bottom" width="34%">
<col align="left" valign="bottom" width="33%">
<col align="left" valign="bottom" width="33%">
<thead><tr class="First Last">
<th align="left">Pharmacokinetic Parameter</th>
<th align="left">Dog Estimate (SD)</th>
<th align="left">Cat Estimate (SD)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Total body clearance/F, mL/min/kg</td>
<td align="left">3.0 ± 0.2</td>
<td align="left">3.98 ± 0.8</td>
</tr>
<tr>
<td align="left">Maximum concentration, C<span class="Sub">max </span>(µg/mL)</td>
<td align="left">2.3 ± 0.3</td>
<td align="left">2.06 ± 0.6</td>
</tr>
<tr>
<td align="left">Time of maximum concentration, T<span class="Sub">max </span>(minutes)</td>
<td align="left">46 ± 27</td>
<td align="left">60 ± 27</td>
</tr>
<tr>
<td align="left">AUC <span class="Sub">0</span> - <span class="Sub">∞</span>(µg∙h/mL)</td>
<td align="left">14.3 ± 1.4</td>
<td align="left">10.82 ± 2.6</td>
</tr>
<tr class="Last">
<td align="left">Terminal plasma elimination half-life, t<span class="Sub">½</span> (hrs)</td>
<td align="left">5.6 ± 1.1</td>
<td align="left">5.52 ± 2.66</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Plasma Concentration of Orbifloxacin vs. Time in Dogs</span></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26e81d72-bb96-497d-ac2f-c9d138f97c09&amp;name=orbax-02.jpg"></p>
<p><span class="Bold">Figure 2. Mean plasma concentration of orbifloxacin vs. time in dogs (2.5 mg/kg = observed values, 7.5 mg/kg = extrapolated values).</span></p>
<p><span class="Bold">Plasma Concentration of Orbifloxacin vs. Time in Cats</span></p>
<p><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26e81d72-bb96-497d-ac2f-c9d138f97c09&amp;name=orbax-03.jpg"></p>
<p><span class="Bold">Figure 3. Mean plasma concentration of orbifloxacin vs. time in cats (2.5 mg/kg = normalized from an actual mean dose of 3.32 mg/kg; 7.5 mg/kg = extrapolated values).</span></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-6.2"></a><p></p>
<p class="First"><span class="Bold">MICROBIOLOGY:</span> Orbifloxacin is bactericidal against a wide range of gram-negative and gram-positive organisms and exerts its antibacterial effect through interference with the bacterial enzyme DNA gyrase which is needed for the maintenance and synthesis of bacterial DNA. The <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of pathogens with the oral tablets isolated in multicentered clinical field trials performed in the United States were determined using Clinical and Laboratory Standards Institute (CLSI) guidelines and are shown in Tables 4, 5, and 6.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: MIC Values<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (µg/mL) of Orbifloxacin Against Urinary Pathogens Isolated Between 1994 and 1996 From Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Dogs</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="23%">
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left">Bacteria Name</th>
<th align="left">Number of Isolates</th>
<th align="left">MIC<span class="Sub">50</span>
</th>
<th align="left">MIC<span class="Sub">90</span>
</th>
<th align="left">MIC Range</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The correlation between the <span class="Italics">in vitro</span> susceptibility data (MIC Values) and clinical response has not been determined.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>There were an insufficient number of isolates to calculate the MIC<span class="Sub">50 </span>or MIC<span class="Sub">90</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left"><span class="Italics">Staphylococcus pseudintermedius</span></td>
<td align="left">5</td>
<td align="left"><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></td>
<td align="left"><a href="#footnote-2" class="Sup">†</a></td>
<td align="left">0.0975 - 0.39</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Proteus mirabilis</span></td>
<td align="left">19</td>
<td align="left">0.78</td>
<td align="left">1.56</td>
<td align="left">0.048 - 1.56</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="left">35</td>
<td align="left">0.0975</td>
<td align="left">0.39</td>
<td align="left">0.024 - ≥25</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td align="left">5</td>
<td align="left"><a href="#footnote-2" class="Sup">†</a></td>
<td align="left"><a href="#footnote-2" class="Sup">†</a></td>
<td align="left">0.003 - 3.12</td>
</tr>
</tbody>
</table>
<a name="table5"></a><table width="75%">
<caption><span>Table 5: MIC Values<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (µg/mL) of Orbifloxacin Against Dermal Pathogens Isolated Between 1994 and 1996 From Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of Dogs</span></caption>
<col align="left" valign="bottom" width="25%">
<col align="left" valign="bottom" width="23%">
<col align="left" valign="bottom" width="17%">
<col align="left" valign="bottom" width="15%">
<col align="left" valign="bottom" width="20%">
<thead><tr class="First Last">
<th align="left" valign="top">Bacteria Name</th>
<th align="left" valign="top">Number of Isolates</th>
<th align="left" valign="top">MIC<span class="Sub">50</span>
</th>
<th align="left" valign="top">MIC<span class="Sub">90</span>
</th>
<th align="left" valign="top">MIC Range</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>The correlation between the <span class="Italics">in vitro</span> susceptibility data (MIC Values) and clinical response has not been determined.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>There were an insufficient number of isolates to calculate the MIC<span class="Sub">50</span> or MIC<span class="Sub">90</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left"><span class="Italics">Staphylococcus pseudintermedius</span></td>
<td align="left">51</td>
<td align="left">0.195</td>
<td align="left">0.39</td>
<td align="left">0.003 - 1.56</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="left">8</td>
<td align="left"><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0.195 - ≥25</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Coagulase +ve staphylococci</span></td>
<td align="left">59</td>
<td align="left">0.195</td>
<td align="left">0.39</td>
<td align="left">0.003 - ≥25</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Pasteurella multocida</span></td>
<td align="left">5</td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0</td>
<td align="left">0.003 - 0.78</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Proteus mirabilis</span></td>
<td align="left">7</td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0.39 - 1.56</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td align="left">14</td>
<td align="left">3.125</td>
<td align="left">12.5</td>
<td align="left">0.39 - ≥25</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Italics">Pseudomonas </span>spp.</td>
<td align="left">18</td>
<td align="left">3.125</td>
<td align="left">12.5</td>
<td align="left">0.02 - ≥25</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="253790" conceptname="Pneumonia due to Klebsiella pneumoniae">Klebsiella pneumonia</span></span></td>
<td align="left">9</td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0.0975 - 0.195</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="left">28</td>
<td align="left">0.0975</td>
<td align="left">0.39</td>
<td align="left">0.012 - 6.25</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Italics">Enterobacter </span>spp.</td>
<td align="left">24</td>
<td align="left">0.0975</td>
<td align="left">0.39</td>
<td align="left">0.012 - 6.25</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Italics">Citrobacter </span>spp.</td>
<td align="left">4</td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0.024 - 0.0975</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td align="left">11</td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0.3 - ≥25</td>
</tr>
<tr class="Botrule">
<td align="left">ß-hemolytic <span class="Italics">streptococci </span>(Group G)</td>
<td align="left">22</td>
<td align="left">0.39</td>
<td align="left">1.56</td>
<td align="left">0.006 - 3.12</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Streptococcus equisimilis</span></td>
<td align="left">10</td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left"><a href="#footnote-4" class="Sup">†</a></td>
<td align="left">0.003 - 0.78</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="75%">
<caption><span>Table 6: MIC Values<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> (µg/mL) of Orbifloxacin Against Dermal Pathogens Isolated Between 1994 and 1996 From Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of Cats</span></caption>
<col align="left" valign="bottom" width="25%">
<col align="left" valign="bottom" width="23%">
<col align="left" valign="bottom" width="17%">
<col align="left" valign="bottom" width="15%">
<col align="left" valign="bottom" width="20%">
<thead><tr class="First Last">
<th align="left" valign="top">Bacteria Name</th>
<th align="left" valign="top">Number of Isolates</th>
<th align="left" valign="top">MIC<span class="Sub">50</span>
</th>
<th align="left" valign="top">MIC<span class="Sub">90</span>
</th>
<th align="left" valign="top">MIC Range</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>The correlation between the <span class="Italics">in vitro</span> susceptibility data (MIC Values) and clinical response has not been determined.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>There were an insufficient number of isolates to calculate the MIC<span class="Sub">50 </span>or MIC<span class="Sub">90</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="left"><span class="Italics">Staphylococcus pseudintermedius</span></td>
<td align="left">25</td>
<td align="left">0.39</td>
<td align="left">0.39</td>
<td align="left">0.024 - 3.125</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="left">7</td>
<td align="left"><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left">0.195 - 0.39</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Coagulase +ve staphylococci</span></td>
<td align="left">32</td>
<td align="left">0.39</td>
<td align="left">0.39</td>
<td align="left">0.024 - 3.125</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Pasteurella multocida</span></td>
<td align="left">47</td>
<td align="left">0.012</td>
<td align="left">0.048</td>
<td align="left">0.003 - 0.195</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td align="left">3</td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left">0.39 - 3.125</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Italics">Pseudomonas </span>spp.</td>
<td align="left">10</td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left">0.195 - 6.25</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="left">17</td>
<td align="left">0.048</td>
<td align="left">0.195</td>
<td align="left">0.024 - 25</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Italics">Enterobacter </span>spp.</td>
<td align="left">12</td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left">0.024 - 0.78</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td align="left">10</td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left">1.56 - 3.125</td>
</tr>
<tr class="Last">
<td align="left">ß-hemolytic <span class="Italics">streptococci </span>(Group G)</td>
<td align="left">14</td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left"><a href="#footnote-6" class="Sup">†</a></td>
<td align="left">0.006 - 1.56</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7"></a><p></p>
<p class="First"><span class="Bold">DRUG INTERACTIONS:</span> Compounds (eg, sucralfate, antacids, and multivitamins) containing divalent and trivalent cations (eg, iron, aluminum, calcium, magnesium, and zinc) may substantially interfere with the absorption of quinolones resulting in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided. The dosage of theophylline should be reduced when used concurrently with fluoroquinolones. Cimetidine has been shown to interfere with the metabolism of fluoroquinolones and should be used with care when used concurrently. Concurrent use of fluoroquinolones with oral cyclosporine is contraindicated. Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CON"></a><a name="section-8"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS:</span> Orbifloxacin and other quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of most species tested, the dog being particularly sensitive to this side effect. Orbifloxacin is contraindicated in immature dogs during the rapid growth phase (between 2 and 8 months of age in small and medium-sized breeds, and up to 18 months of age in large and giant breeds). Orbifloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS:</span> Prescribing antibacterial drugs in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens.</p>
<p>The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span> has also been reported post-approval in cats. In some cases, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> has been temporary. DO NOT EXCEED 3.4 mg/lb (7.5 mg/kg) BODY WEIGHT PER DAY IN CATS.</p>
<p>Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species.</p>
<p>Administer orbifloxacin with caution in the presence of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>/ impairment. The safety of orbifloxacin in animals that are used for breeding or that are pregnant and/or lactating has not been demonstrated.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">WARNINGS: For use in animals only. Do not exceed 7.5 mg/kg body weight per day in cats. Keep out of the reach of children.</span></p>
<p>Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposure. Individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="TAS"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">TARGET ANIMAL SAFETY:</span> Orbifloxacin administered to young, clinically healthy, adult dogs and cats at doses of 7.5 mg/kg, 22.5 mg/kg, and 37.5 mg/kg for 30 consecutive days was well tolerated. At the exaggerated doses of 22.5 and 37.5 mg/kg/day, orbifloxacin caused mild gastrointestinal effects (soft feces) in both male and female cats. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> (males only), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (males only), reduced food consumption with subsequent reduced body weight were evident in cats administered ORBAX<span class="Sup">® </span>(orbitfloxacin) Tablets at 75 mg/kg/day for 10 days. Orbifloxacin and other quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of most species tested, the dog being particularly sensitive to this side effect. In 8- to 10-week-old beagle puppies dosed daily with orbifloxacin for 30 days, microscopic lesions consistent with fluoroquinolone-induced <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> of the articular cartilage was seen in only one of eight dogs dosed at 12.5 mg/kg, and in all eight dogs dosed at 25 mg/kg. (See <span class="Bold"><a href="#CON">CONTRAINDICATIONS</a></span>.) No <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> was noted in 12-week-old kittens administered orbifloxacin at doses as high as 25 mg/kg for 1 month.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS:</span> In clinical trials, when the drug was administered at 2.5 mg/ kg/day, no drug-related adverse reactions were reported.</p>
<p><span class="Bold">Post Approval Experience with ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets (Rev. 2010): The following adverse events are based on postapproval adverse drug experience reporting with ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reporting frequency:</span></p>
<p>CAT: <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, abnormal retina, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>. In some cases, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> has been temporary.</p>
<p>DOG: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <span class="Underline">http://www.fda.gov/AnimalVeterinary/SafetyHealth.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">HOW SUPPLIED:</span> ORBAX<span class="Sup">® </span>(orbifloxacin) Tablets are available in the following presentations:</p>
<table class="Noautorules" width="65%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="45%">
<col align="left" valign="bottom" width="40%">
<tbody class="Headless">
<tr>
<td align="left">22.7 mg:</td>
<td align="left">Bottles of 250 green, E-Z Break, single-scored tablets</td>
<td align="left">NDC 0061-1141-01</td>
</tr>
<tr>
<td align="left">68 mg:</td>
<td align="left">Bottles of 100 blue, E-Z Break, single-scored tablets</td>
<td align="left">NDC 0061-1174-01</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">STORAGE CONDITIONS:</span> Store between 2° and 30°C (36° and 86°F). Protect from excessive moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">For technical assistance or to report a suspected adverse reaction call 1-800-224-5318.</p>
<p>Made in USA<br>Intervet Inc (d/b/a Merck Animal Health)<br>Summit, NJ 07901</p>
<p>© 1997, 2010, 2014 Intervet Inc. a subsidiary of Merck &amp; Co.<br>All rights reserved.</p>
<p>For patent information:<br><span class="Underline">http://www.merck.com/product/patent/home.html</span>.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL- 22.7 mg Tablet Bottle Label</h1>
<p class="First">250 Tablets <span class="Bold">22.7 mg</span></p>
<p><span class="Bold">NDC</span> 0061-1141-01</p>
<p><span class="Bold">ORBAX<span class="Sup">®</span><br>(orbifloxacin)</span></p>
<p>Tablets for Dogs and Cats Only</p>
<p><span class="Bold">Caution:</span> Federal law restricts this drug to use<br>by or on the order of a licensed veterinarian.</p>
<p><span class="Bold">Federal law prohibits the extra label use<br>of this drug in food-producing animals.</span></p>
<p>NADA #141-081, Approved by FDA.</p>
<p><span class="Bold">MERCK</span><br>Animal Health</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL- 22.7 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26e81d72-bb96-497d-ac2f-c9d138f97c09&amp;name=orbax-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL- 68 mg Tablet Bottle Label</h1>
<p class="First">100 Tablets <span class="Bold">68 mg</span></p>
<p><span class="Bold">NDC</span> 0061-1174-01</p>
<p><span class="Bold">ORBAX<span class="Sup">®</span><br>(orbifloxacin)</span></p>
<p>Tablets for Dogs and Cats Only</p>
<p><span class="Bold">Caution:</span> Federal law restricts this drug to use<br>by or on the order of a licensed veterinarian.</p>
<p><span class="Bold">Federal law prohibits the extra label use<br>of this drug in food-producing animals.</span></p>
<p>NADA #141-081, Approved by FDA.</p>
<p><span class="Bold">MERCK</span><br>Animal Health</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL- 68 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26e81d72-bb96-497d-ac2f-c9d138f97c09&amp;name=orbax-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORBAX 		
					</strong><br><span class="contentTableReg">orbifloxacin tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0061-1141</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Orbifloxacin</strong> (Orbifloxacin) </td>
<td class="formItem">Orbifloxacin</td>
<td class="formItem">22.7 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0061-1141-01</td>
<td class="formItem">250  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141081</td>
<td class="formItem">04/22/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORBAX 		
					</strong><br><span class="contentTableReg">orbifloxacin tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0061-1174</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Orbifloxacin</strong> (Orbifloxacin) </td>
<td class="formItem">Orbifloxacin</td>
<td class="formItem">68 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0061-1174-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141081</td>
<td class="formItem">04/22/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bimeda, Inc.</td>
<td class="formItem"></td>
<td class="formItem">060492923</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f05e75a3-5770-4ab5-b072-dd22ec5fa480</div>
<div>Set id: 26e81d72-bb96-497d-ac2f-c9d138f97c09</div>
<div>Version: 1</div>
<div>Effective Time: 20140807</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
